Abstract
Allosteric drugs bind to sites which are usually less conserved evolutionarily as compared to orthosteric sites. As such, they can discriminate between closely related proteins, have fewer side effects, and a consequent lower concentration can convey a lesser likelihood of receptor desensitization. However, an allosteric mode of action may also make the results of preclinical and animal experiments less predictive. The sensitivity of the allosteric consequences to the environment further increases the importance of accounting for patient population diversity. Even subtle differences in protein sequence, in cellular metabolic states or in target tissues, can result in different outcomes. This mini-hot-topic issue of CTMC showcases some successes and challenges of allosteric drug development through the examples of seventransmembrane (GPCR), AMPA, NMDA and metabotropic glutamate receptors, as well as the morpheein model of allosterism involved in inherent metabolic errors. Finally, the development of allo-network drugs, which are allosteric drugs acting indirectly on the neighborhood of the pharmacological target in protein-protein interaction or signaling networks, is described.
Keywords: Allo-network drugs, allosteric drugs, glutamatergic transmission, GPCR receptors, networks, quaternary structure, SAR landscapes, schizophrenia
Current Topics in Medicinal Chemistry
Title:Editorial (Hot Topic: From Allosteric Drugs to Allo-Network Drugs: State of the Art and Trends of Design, Synthesis and Computational Methods)
Volume: 13 Issue: 1
Author(s): Peter Csermely, Ruth Nussinov and Andras Szilagyi
Affiliation:
Keywords: Allo-network drugs, allosteric drugs, glutamatergic transmission, GPCR receptors, networks, quaternary structure, SAR landscapes, schizophrenia
Abstract: Allosteric drugs bind to sites which are usually less conserved evolutionarily as compared to orthosteric sites. As such, they can discriminate between closely related proteins, have fewer side effects, and a consequent lower concentration can convey a lesser likelihood of receptor desensitization. However, an allosteric mode of action may also make the results of preclinical and animal experiments less predictive. The sensitivity of the allosteric consequences to the environment further increases the importance of accounting for patient population diversity. Even subtle differences in protein sequence, in cellular metabolic states or in target tissues, can result in different outcomes. This mini-hot-topic issue of CTMC showcases some successes and challenges of allosteric drug development through the examples of seventransmembrane (GPCR), AMPA, NMDA and metabotropic glutamate receptors, as well as the morpheein model of allosterism involved in inherent metabolic errors. Finally, the development of allo-network drugs, which are allosteric drugs acting indirectly on the neighborhood of the pharmacological target in protein-protein interaction or signaling networks, is described.
Export Options
About this article
Cite this article as:
Csermely Peter, Nussinov Ruth and Szilagyi Andras, Editorial (Hot Topic: From Allosteric Drugs to Allo-Network Drugs: State of the Art and Trends of Design, Synthesis and Computational Methods), Current Topics in Medicinal Chemistry 2013; 13 (1) . https://dx.doi.org/10.2174/1568026611313010002
DOI https://dx.doi.org/10.2174/1568026611313010002 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potassium Channels as Targets for the Management of Pain
Central Nervous System Agents in Medicinal Chemistry Design, Synthesis and Antimicrobial Evaluation of Novel 1,3-Oxazolidin-2- one Derivatives
Current Topics in Medicinal Chemistry COVID-19 Infection in Pregnancy: A Review
Infectious Disorders - Drug Targets Assessment of COVID-19 Treatment Advised in Different Ethnic Populations
Current Drug Safety Developments of Combretastatin A-4 Derivatives as Anticancer Agents
Current Medicinal Chemistry Efficacy and Safety of Thrombolysis in COVID-19 Related ARDS
Recent Advances in Anti-Infective Drug Discovery 20th National Congress and Conference Abstracts
Endocrine, Metabolic & Immune Disorders - Drug Targets Standards and Novel Therapeutic Options in the Treatment of Patients with Soft Tissue Sarcoma
Reviews on Recent Clinical Trials Anti-leishmanial Activity of Gossypium hirsutum L., Ferula assa-foetida L. and Artemisia aucheri Boiss. Extracts by Colorimetric Assay
Anti-Infective Agents Non-Nucleoside HIV-1 Reverse Transcriptase (RT) Inhibitors: Past, Present, and Future Perspectives
Current Pharmaceutical Design Potent Chemopreventive Agents Against Pancreatic Cancer
Current Cancer Drug Targets Cascade Reactions Involving Aromatic N-Heterocycles: C-N Bond Formation as Key-step Towards the Synthesis of N-fused Polycyclic Heterocycles
Current Organic Chemistry Model Systems for Pulmonary Infectious Diseases: Paradigms of Anthrax and Tuberculosis
Current Topics in Medicinal Chemistry Performance of Machine Learning Methods for Ligand-Based Virtual Screening
Combinatorial Chemistry & High Throughput Screening Selective Pharmacological Inhibition of the Pacemaker Channel Isoforms (HCN1-4) as New Possible Therapeutical Targets
Current Medicinal Chemistry A Brief Review on Software Implementations and Algorithm Enhancements of Chou’s Pseudo-Amino Acid Compositions
Current Proteomics Endocannabinoids as Regulators of Transient Receptor Potential (TRP)Channels: a Further Opportunity to Develop New Endocannabinoid-Based Therapeutic Drugs
Current Medicinal Chemistry Targeting Bacterial RNA Polymerase σ70 for Development of Broadspectrum Antisense Antibacterials
Recent Patents on Anti-Infective Drug Discovery Mass Spectrometry-Based Approaches for the Detection of Proteins of Staphylococcus Species
Infectious Disorders - Drug Targets Vitamin C: Basic Metabolism and Its Function as an Index of Oxidative Stress
Current Medicinal Chemistry